ÂÜÀòÂÒÂ×

Pri­or to join­ing Metageno­mi, Sarah was Chief Med­ical Offi­cer of Maze Ther­a­peu­tics where she built and led non­clin­i­cal and clin­i­cal devel­op­ment efforts to trans­late insights from human genet­ics into nov­el ther­a­peu­tics. Ear­li­er she was Chief Med­ical Offi­cer of Nohla Ther­a­peu­tics lead­ing clin­i­cal devel­op­ment of a uni­ver­sal cell ther­a­py for hema­to­log­ic malig­nan­cies. Oth­er exec­u­tive lead­er­ship roles have includ­ed Head of Glob­al Clin­i­cal Devel­op­ment at Bio­Marin where she advanced a broad port­fo­lio of pro­grams involv­ing bio­log­ics, anti­sense oligoneu­cleotides and gene ther­a­pies for rare genet­i­cal­ly defined dis­eases, and Senior Vice Pres­i­dent at Medi­va­tion where she led trans­la­tion­al and ear­ly devel­op­ment activ­i­ties as well as late-stage devel­op­ment of enza­lu­tamide (XTAN­DI™) for advanced prostate cancer.

Sarah cur­rent­ly serves on the Board of Direc­tors at Pro­tag­o­nist Ther­a­peu­tics and Neoleukin Ther­a­peu­tics. She trained in inter­nal med­i­cine at Johns Hop­kins Hos­pi­tal, received an MD from the Uni­ver­si­ty of Cal­i­for­nia, San Fran­cis­co, a Ph.D. in bio­engi­neer­ing from the Uni­ver­si­ty of Cal­i­for­nia, Berke­ley, and a B.S. in engi­neer­ing sci­ence from Dart­mouth College.